Result for
Topic: Vaccines and Immunity
March 10, 2021
Vaccine Effectiveness after 1st and 2nd Dose of the BNT162b2 MRNA Covid-19 Vaccine in Long-Term Care Facility Residents and Healthcare Workers – a Danish Cohort Study
[Pre-print, not peer-reviewed] A retrospective registry- and population-based observational cohort study in Denmark estimated that the Pfizer/BioNTech vaccine efficacy within 7 days of receipt was 52% among long term care facility residents (LTCF, n = 39,040) and 46% among health care workers (HCW, n = 331,039), which increased to 64% and 90%, respectively, beyond 7…
Predictors of the Intention to Receive a SARS-CoV-2 Vaccine
A study of 1,054 US adults surveyed in October 2020 indicated factors associated with intention to receive a COVID-19 vaccine were greater perceptions of vulnerability to COVID-19, receipt of a flu vaccine at the time of the study, liberal political orientation, non-Black race, male gender, and a lower preference for natural versus synthetic medications. While…
Comparison of COVID-19 Vaccine Prioritization Strategies in the United States
[Pre-print, not peer-reviewed] A static simulation model using California as an example to compare the impact of different vaccine prioritization strategies in the United States found that prioritizing older individuals averted the highest proportion of disability-adjusted life years (DALYs, 40% for 5 million individuals vaccinated) and deaths (65%), but the lowest proportion of cases (12%)….
The Plasmablast Response to SARS-CoV-2 MRNA Vaccination Is Dominated by Non-Neutralizing Antibodies That Target Both the NTD and the RBD
[Pre-print, not peer-reviewed] A study of vaccine-induced polyclonal antibodies and monoclonal antibodies (mAbs) from subjects who received SARS-CoV-2 mRNA vaccines found that polyclonal antibody responses were robust and comparable to or exceeded those observed after natural infection. However, most vaccine-induced mAbs did not demonstrate neutralizing activity. Neutralizing activity of N-terminal domain (NTD) mAbs, but not…
March 9, 2021
SARS-CoV-2-Specific T Cell Memory Is Sustained in COVID-19 Convalescents for 8 Months with Successful Development of Stem Cell-like Memory T Cells
[Pre-print, not peer-reviewed] Whole blood analysis from 94 individuals who had been infected with SARS-CoV-2 in South Korea found that, SARS-CoV-2-specific memory T cell responses were maintained at up to 8 months post-symptom onset. Among 30 individuals with longitudinal samples beyond the first month, no significant differences in memory T cell responses were observed between…
COVID-19 Vaccine Response in Pregnant and Lactating Women a Cohort Study
[Pre-print, not peer-reviewed] The Pfizer-BioNTech and Moderna vaccines elicited similar immune responses among pregnant (n=84) and lactating (n=31) women compared to non-pregnant reproductive-age women (n=16). All vaccine-induced SARS-CoV-2-specific antibody titers were higher compared to titers from a group of pregnant women (n=37) that had SARS-CoV-2 infection 4-12 weeks prior. Vaccine-induced antibodies were detected in all…
Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBV152: Interim Results from a Double-Blind, Randomised, Multicentre, Phase 2 Trial, and 3-Month Follow-up of a Double-Blind, Randomised Phase 1 Trial
Interim results from a double-blind randomized phase 2 trial (n=380) of the Bharat Biotech whole-virion inactivated SARS-CoV-2 vaccine (BBV152) show robust neutralizing titers against wild-type SARS-CoV-2 at day 56 following two doses administered on day 0 and day 28. In a plaque-reduction neutralization test, the 6 µg dose group compared to the 3 µg dose…
Serological Evidence of Human Infection with SARS-CoV-2: A Systematic Review and Meta-Analysis
Seroprevalence of SARS-CoV-2-specific antibodies varied dramatically across WHO regions, according to a systematic review and meta-analysis including over 5 million participants from 400 serosurveys. The Southeast Asia region had the highest seroprevalence (20%), while the Western Pacific region, including Australia and New Zealand, had the lowest (1.7%). In a subset of serosurveys with higher quality…
Acute Allergic Reactions to MRNA COVID-19 Vaccines
Among employees of Mass General Brigham (MGB), a Boston-based hospital and physicians network, who received their first dose of either the Pfizer-BioNTech or Moderna vaccine (n=64,900), acute allergic reactions of any type were reported by 1,365 employees overall (2.1%) and anaphylaxis was reported by 16 employees (2.5 cases per 10,000 vaccinations).. Among those reporting anaphylaxis,…
March 8, 2021
Robust SARS-CoV-2-Specific T Cell Immunity Is Maintained at 6 Months Following Primary Infection
Functional SARS-CoV-2-specific T cell responses were retained 6 months after initial SARS-CoV-2 infection among 100 convalescent donors between March and April 2020. Interferon (IFN)-γ ELISPOT analysis was used to determine the magnitude of the T cell response. Cell responses were present among all donors and characterized by predominant CD4+ T cell responses with strong interleukin…
Previous page Next page